| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 245 | 2024 | 1823 | 42.420 |
Why?
|
| Atherosclerosis | 126 | 2025 | 828 | 30.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 126 | 2023 | 711 | 27.100 |
Why?
|
| Coronary Artery Disease | 76 | 2025 | 742 | 16.210 |
Why?
|
| Cardiology | 49 | 2024 | 468 | 14.430 |
Why?
|
| Cholesterol, LDL | 79 | 2024 | 554 | 11.700 |
Why?
|
| Anticholesteremic Agents | 37 | 2023 | 230 | 11.290 |
Why?
|
| Dyslipidemias | 35 | 2022 | 227 | 10.000 |
Why?
|
| United States | 259 | 2024 | 10494 | 8.440 |
Why?
|
| Diabetes Mellitus | 49 | 2024 | 845 | 8.380 |
Why?
|
| American Heart Association | 55 | 2024 | 289 | 8.270 |
Why?
|
| Stroke | 55 | 2024 | 957 | 8.250 |
Why?
|
| Risk Assessment | 117 | 2025 | 3307 | 7.740 |
Why?
|
| Risk Factors | 233 | 2025 | 9903 | 7.450 |
Why?
|
| Cholesterol | 39 | 2023 | 521 | 7.310 |
Why?
|
| Primary Prevention | 41 | 2024 | 163 | 6.670 |
Why?
|
| Humans | 641 | 2025 | 122349 | 6.460 |
Why?
|
| Hypercholesterolemia | 26 | 2024 | 226 | 6.100 |
Why?
|
| Medication Adherence | 23 | 2022 | 384 | 5.990 |
Why?
|
| Secondary Prevention | 27 | 2022 | 210 | 5.850 |
Why?
|
| Myocardial Infarction | 41 | 2023 | 994 | 5.720 |
Why?
|
| Hypertension | 39 | 2024 | 1274 | 5.680 |
Why?
|
| Practice Patterns, Physicians' | 28 | 2023 | 710 | 5.600 |
Why?
|
| Middle Aged | 271 | 2025 | 25655 | 5.470 |
Why?
|
| Registries | 52 | 2024 | 1368 | 5.420 |
Why?
|
| Heart Failure | 51 | 2024 | 2125 | 5.320 |
Why?
|
| Practice Guidelines as Topic | 46 | 2024 | 1247 | 5.310 |
Why?
|
| Coronary Disease | 32 | 2024 | 635 | 5.180 |
Why?
|
| Aged | 219 | 2024 | 18799 | 5.100 |
Why?
|
| Healthcare Disparities | 23 | 2023 | 410 | 4.890 |
Why?
|
| Lipoprotein(a) | 20 | 2024 | 113 | 4.840 |
Why?
|
| Percutaneous Coronary Intervention | 24 | 2023 | 222 | 4.760 |
Why?
|
| Vascular Calcification | 13 | 2024 | 52 | 4.640 |
Why?
|
| Hypolipidemic Agents | 16 | 2021 | 176 | 4.580 |
Why?
|
| Guideline Adherence | 32 | 2020 | 376 | 4.450 |
Why?
|
| Male | 327 | 2025 | 59559 | 4.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 23 | 2024 | 1204 | 4.390 |
Why?
|
| Coronary Artery Bypass | 24 | 2023 | 486 | 4.370 |
Why?
|
| Lipids | 25 | 2022 | 512 | 4.280 |
Why?
|
| Female | 324 | 2025 | 64923 | 4.110 |
Why?
|
| Myocardial Ischemia | 12 | 2024 | 330 | 4.100 |
Why?
|
| Platelet Aggregation Inhibitors | 17 | 2021 | 256 | 4.030 |
Why?
|
| Proprotein Convertase 9 | 14 | 2024 | 67 | 3.710 |
Why?
|
| Behavioral Risk Factor Surveillance System | 17 | 2023 | 51 | 3.650 |
Why?
|
| United States Department of Veterans Affairs | 19 | 2024 | 644 | 3.590 |
Why?
|
| Adult | 159 | 2025 | 28764 | 3.480 |
Why?
|
| Veterans | 21 | 2024 | 1711 | 3.420 |
Why?
|
| Eicosapentaenoic Acid | 9 | 2023 | 78 | 3.370 |
Why?
|
| Acute Coronary Syndrome | 15 | 2024 | 197 | 3.300 |
Why?
|
| Prevalence | 46 | 2024 | 2373 | 3.170 |
Why?
|
| Hyperlipidemias | 13 | 2023 | 174 | 3.160 |
Why?
|
| Renal Insufficiency, Chronic | 21 | 2023 | 713 | 3.120 |
Why?
|
| Heart Diseases | 20 | 2023 | 482 | 2.950 |
Why?
|
| Plaque, Atherosclerotic | 13 | 2024 | 119 | 2.880 |
Why?
|
| Atrial Fibrillation | 17 | 2023 | 621 | 2.870 |
Why?
|
| Peripheral Arterial Disease | 12 | 2022 | 266 | 2.870 |
Why?
|
| Cholesterol, HDL | 25 | 2024 | 347 | 2.850 |
Why?
|
| Health Expenditures | 15 | 2020 | 102 | 2.850 |
Why?
|
| Aspirin | 11 | 2023 | 222 | 2.850 |
Why?
|
| Cigarette Smoking | 5 | 2021 | 55 | 2.830 |
Why?
|
| Hypertriglyceridemia | 7 | 2023 | 100 | 2.820 |
Why?
|
| Biomarkers | 66 | 2024 | 2945 | 2.770 |
Why?
|
| Ezetimibe | 15 | 2022 | 95 | 2.750 |
Why?
|
| Blood Pressure | 24 | 2024 | 1314 | 2.690 |
Why?
|
| Electronic Nicotine Delivery Systems | 4 | 2020 | 51 | 2.690 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2023 | 1034 | 2.670 |
Why?
|
| Drug Costs | 5 | 2019 | 61 | 2.610 |
Why?
|
| Hyperlipoproteinemia Type II | 11 | 2023 | 84 | 2.590 |
Why?
|
| Nurse Practitioners | 5 | 2021 | 43 | 2.460 |
Why?
|
| Physician Assistants | 5 | 2021 | 59 | 2.420 |
Why?
|
| ST Elevation Myocardial Infarction | 11 | 2022 | 104 | 2.390 |
Why?
|
| Smoking Cessation | 9 | 2024 | 194 | 2.380 |
Why?
|
| Cross-Sectional Studies | 38 | 2024 | 3302 | 2.370 |
Why?
|
| Drug Prescriptions | 12 | 2020 | 215 | 2.320 |
Why?
|
| Risk Reduction Behavior | 13 | 2022 | 132 | 2.290 |
Why?
|
| Carotid Artery Diseases | 10 | 2020 | 147 | 2.250 |
Why?
|
| Veterans Health | 9 | 2021 | 172 | 2.200 |
Why?
|
| Quality Improvement | 8 | 2020 | 620 | 2.130 |
Why?
|
| Treatment Outcome | 82 | 2024 | 12049 | 2.110 |
Why?
|
| Social Determinants of Health | 8 | 2022 | 110 | 2.110 |
Why?
|
| Lipoproteins | 12 | 2022 | 178 | 2.090 |
Why?
|
| Sex Factors | 23 | 2022 | 1238 | 2.030 |
Why?
|
| C-Reactive Protein | 14 | 2024 | 405 | 2.030 |
Why?
|
| Ambulatory Care | 11 | 2022 | 376 | 2.000 |
Why?
|
| Coronary Vessels | 13 | 2023 | 525 | 2.000 |
Why?
|
| Calcium | 14 | 2024 | 1095 | 1.980 |
Why?
|
| Hospital Mortality | 22 | 2024 | 996 | 1.970 |
Why?
|
| Cardiovascular Agents | 5 | 2024 | 86 | 1.910 |
Why?
|
| Football | 5 | 2014 | 29 | 1.900 |
Why?
|
| Telemedicine | 9 | 2024 | 422 | 1.880 |
Why?
|
| Time Factors | 52 | 2024 | 6182 | 1.880 |
Why?
|
| Triglycerides | 18 | 2024 | 560 | 1.840 |
Why?
|
| Aged, 80 and over | 58 | 2024 | 6293 | 1.840 |
Why?
|
| Aortic Valve Stenosis | 9 | 2023 | 322 | 1.820 |
Why?
|
| Brain Ischemia | 5 | 2023 | 258 | 1.810 |
Why?
|
| Cardiovascular System | 3 | 2024 | 99 | 1.800 |
Why?
|
| Health Status Disparities | 6 | 2024 | 217 | 1.760 |
Why?
|
| Smoking | 15 | 2024 | 1028 | 1.650 |
Why?
|
| Women's Health | 3 | 2020 | 129 | 1.650 |
Why?
|
| Tobacco, Smokeless | 3 | 2021 | 13 | 1.650 |
Why?
|
| Antihypertensive Agents | 14 | 2024 | 392 | 1.640 |
Why?
|
| Delivery of Health Care | 12 | 2022 | 604 | 1.620 |
Why?
|
| Primary Health Care | 10 | 2021 | 748 | 1.620 |
Why?
|
| Retrospective Studies | 69 | 2024 | 15858 | 1.580 |
Why?
|
| Cause of Death | 10 | 2024 | 453 | 1.580 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 360 | 1.570 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 378 | 1.560 |
Why?
|
| Pandemics | 10 | 2023 | 1102 | 1.550 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2019 | 35 | 1.520 |
Why?
|
| Incidence | 42 | 2025 | 3018 | 1.510 |
Why?
|
| Comorbidity | 26 | 2023 | 1490 | 1.500 |
Why?
|
| Age Factors | 28 | 2024 | 2777 | 1.470 |
Why?
|
| Mortality | 10 | 2024 | 223 | 1.470 |
Why?
|
| Retirement | 4 | 2014 | 18 | 1.460 |
Why?
|
| Young Adult | 42 | 2024 | 8775 | 1.460 |
Why?
|
| Preventive Medicine | 3 | 2019 | 22 | 1.460 |
Why?
|
| Eligibility Determination | 6 | 2019 | 39 | 1.450 |
Why?
|
| Health Services Accessibility | 9 | 2022 | 581 | 1.440 |
Why?
|
| Clinical Decision-Making | 9 | 2021 | 267 | 1.420 |
Why?
|
| Vaping | 2 | 2021 | 28 | 1.420 |
Why?
|
| Health Care Costs | 10 | 2021 | 361 | 1.420 |
Why?
|
| Obesity | 19 | 2022 | 2085 | 1.420 |
Why?
|
| Odds Ratio | 22 | 2022 | 1234 | 1.410 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 1022 | 1.400 |
Why?
|
| Income | 11 | 2024 | 133 | 1.390 |
Why?
|
| Surveys and Questionnaires | 17 | 2023 | 3628 | 1.370 |
Why?
|
| Health Behavior | 7 | 2022 | 378 | 1.370 |
Why?
|
| Dicarboxylic Acids | 4 | 2023 | 34 | 1.350 |
Why?
|
| Physicians, Primary Care | 3 | 2021 | 94 | 1.350 |
Why?
|
| Nutrition Surveys | 11 | 2024 | 279 | 1.340 |
Why?
|
| Prospective Studies | 42 | 2024 | 5974 | 1.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 10 | 2021 | 816 | 1.310 |
Why?
|
| Prediabetic State | 4 | 2024 | 57 | 1.300 |
Why?
|
| Hospitalization | 22 | 2024 | 1727 | 1.290 |
Why?
|
| Fish Oils | 2 | 2021 | 82 | 1.290 |
Why?
|
| Logistic Models | 20 | 2021 | 1772 | 1.250 |
Why?
|
| Inpatients | 10 | 2023 | 490 | 1.240 |
Why?
|
| Life Style | 7 | 2021 | 396 | 1.220 |
Why?
|
| Follow-Up Studies | 31 | 2022 | 5013 | 1.200 |
Why?
|
| Internet | 3 | 2020 | 373 | 1.200 |
Why?
|
| Attitude of Health Personnel | 4 | 2020 | 635 | 1.190 |
Why?
|
| Patient Selection | 6 | 2019 | 685 | 1.190 |
Why?
|
| Health Personnel | 4 | 2020 | 500 | 1.180 |
Why?
|
| Evidence-Based Medicine | 10 | 2020 | 605 | 1.170 |
Why?
|
| Fatty Acids | 4 | 2023 | 337 | 1.170 |
Why?
|
| Health Surveys | 8 | 2024 | 235 | 1.140 |
Why?
|
| Quality Indicators, Health Care | 8 | 2020 | 214 | 1.140 |
Why?
|
| Apolipoproteins B | 7 | 2024 | 131 | 1.120 |
Why?
|
| Reminder Systems | 2 | 2018 | 60 | 1.110 |
Why?
|
| Clinical Trials as Topic | 10 | 2024 | 1084 | 1.110 |
Why?
|
| Anticoagulants | 8 | 2021 | 582 | 1.090 |
Why?
|
| Age of Onset | 4 | 2025 | 577 | 1.080 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 6 | 2019 | 87 | 1.080 |
Why?
|
| Body Mass Index | 10 | 2021 | 1463 | 1.080 |
Why?
|
| Hypoglycemic Agents | 8 | 2024 | 412 | 1.070 |
Why?
|
| Fibric Acids | 2 | 2023 | 6 | 1.060 |
Why?
|
| Quality of Health Care | 5 | 2019 | 391 | 1.050 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2023 | 425 | 1.050 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 456 | 1.040 |
Why?
|
| Exercise | 10 | 2023 | 790 | 1.040 |
Why?
|
| Postoperative Complications | 11 | 2021 | 2997 | 1.030 |
Why?
|
| Databases, Factual | 14 | 2024 | 1158 | 1.030 |
Why?
|
| Noncommunicable Diseases | 3 | 2023 | 16 | 1.030 |
Why?
|
| Communication | 5 | 2021 | 505 | 1.020 |
Why?
|
| Stroke Volume | 7 | 2024 | 446 | 1.010 |
Why?
|
| Diabetes Complications | 6 | 2021 | 197 | 1.000 |
Why?
|
| Fibrinolytic Agents | 4 | 2020 | 199 | 0.990 |
Why?
|
| Sex Characteristics | 3 | 2020 | 308 | 0.990 |
Why?
|
| Metabolic Syndrome | 8 | 2024 | 325 | 0.980 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2020 | 2573 | 0.980 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2021 | 14 | 0.980 |
Why?
|
| Severity of Illness Index | 15 | 2024 | 2817 | 0.980 |
Why?
|
| Betacoronavirus | 4 | 2020 | 289 | 0.960 |
Why?
|
| Tobacco Use | 3 | 2021 | 24 | 0.960 |
Why?
|
| Preventive Health Services | 3 | 2020 | 53 | 0.960 |
Why?
|
| Blood Glucose | 8 | 2022 | 1103 | 0.940 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2023 | 210 | 0.930 |
Why?
|
| Prognosis | 28 | 2025 | 4490 | 0.930 |
Why?
|
| Neoplasms | 6 | 2023 | 2753 | 0.930 |
Why?
|
| Thiophenes | 2 | 2014 | 60 | 0.920 |
Why?
|
| Social Media | 3 | 2022 | 106 | 0.920 |
Why?
|
| Ventricular Function, Left | 5 | 2022 | 500 | 0.910 |
Why?
|
| Periodontal Diseases | 3 | 2023 | 20 | 0.910 |
Why?
|
| Lipid Regulating Agents | 2 | 2020 | 6 | 0.910 |
Why?
|
| Predictive Value of Tests | 18 | 2023 | 2080 | 0.900 |
Why?
|
| Prescription Drugs | 2 | 2014 | 52 | 0.900 |
Why?
|
| Transcatheter Aortic Valve Replacement | 6 | 2023 | 189 | 0.900 |
Why?
|
| Global Health | 10 | 2024 | 555 | 0.900 |
Why?
|
| Inflammation | 6 | 2020 | 1392 | 0.900 |
Why?
|
| Calcinosis | 5 | 2022 | 167 | 0.890 |
Why?
|
| Adolescent | 33 | 2024 | 18959 | 0.880 |
Why?
|
| Survival Rate | 17 | 2024 | 1997 | 0.880 |
Why?
|
| Tobacco Products | 2 | 2021 | 61 | 0.880 |
Why?
|
| Rivaroxaban | 2 | 2021 | 55 | 0.880 |
Why?
|
| Cohort Studies | 25 | 2024 | 4643 | 0.870 |
Why?
|
| Cerebrovascular Disorders | 4 | 2024 | 117 | 0.870 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2023 | 169 | 0.850 |
Why?
|
| Influenza Vaccines | 3 | 2022 | 468 | 0.840 |
Why?
|
| Piperazines | 2 | 2014 | 227 | 0.830 |
Why?
|
| Physicians | 3 | 2023 | 582 | 0.830 |
Why?
|
| Medication Therapy Management | 6 | 2018 | 25 | 0.830 |
Why?
|
| Population Surveillance | 2 | 2022 | 381 | 0.830 |
Why?
|
| Multivariate Analysis | 11 | 2021 | 1407 | 0.820 |
Why?
|
| Policy Making | 2 | 2019 | 58 | 0.820 |
Why?
|
| Pakistan | 9 | 2024 | 75 | 0.820 |
Why?
|
| Publishing | 1 | 2024 | 104 | 0.820 |
Why?
|
| Natriuretic Peptide, Brain | 10 | 2023 | 276 | 0.810 |
Why?
|
| Patient Care Planning | 2 | 2021 | 122 | 0.810 |
Why?
|
| Shock, Cardiogenic | 9 | 2023 | 189 | 0.810 |
Why?
|
| Medicaid | 2 | 2021 | 239 | 0.800 |
Why?
|
| India | 8 | 2020 | 218 | 0.800 |
Why?
|
| Dietary Supplements | 4 | 2021 | 460 | 0.790 |
Why?
|
| Acute Kidney Injury | 5 | 2022 | 606 | 0.790 |
Why?
|
| Simvastatin | 4 | 2017 | 75 | 0.790 |
Why?
|
| Foreign-Body Migration | 2 | 2015 | 74 | 0.780 |
Why?
|
| Societies, Medical | 4 | 2024 | 673 | 0.780 |
Why?
|
| Myocardial Perfusion Imaging | 3 | 2019 | 57 | 0.780 |
Why?
|
| Cinnamomum zeylanicum | 1 | 2021 | 1 | 0.780 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 23 | 0.780 |
Why?
|
| Physician-Patient Relations | 3 | 2021 | 423 | 0.770 |
Why?
|
| Coronary Angiography | 10 | 2024 | 417 | 0.770 |
Why?
|
| Plant Preparations | 1 | 2021 | 18 | 0.770 |
Why?
|
| Marijuana Use | 1 | 2021 | 8 | 0.760 |
Why?
|
| Cardiotonic Agents | 2 | 2022 | 135 | 0.760 |
Why?
|
| Unsafe Sex | 1 | 2021 | 20 | 0.760 |
Why?
|
| Congresses as Topic | 4 | 2024 | 164 | 0.760 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 39 | 0.750 |
Why?
|
| Docosahexaenoic Acids | 2 | 2019 | 66 | 0.750 |
Why?
|
| Troponin T | 9 | 2023 | 245 | 0.750 |
Why?
|
| Diabetic Nephropathies | 2 | 2021 | 110 | 0.750 |
Why?
|
| Phytotherapy | 1 | 2021 | 49 | 0.750 |
Why?
|
| Military Medicine | 1 | 2021 | 47 | 0.750 |
Why?
|
| Preoperative Care | 4 | 2012 | 350 | 0.750 |
Why?
|
| Diet Therapy | 1 | 2021 | 42 | 0.750 |
Why?
|
| Europe | 5 | 2024 | 369 | 0.740 |
Why?
|
| Office Visits | 2 | 2019 | 75 | 0.740 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 152 | 0.730 |
Why?
|
| Outpatients | 3 | 2018 | 254 | 0.730 |
Why?
|
| Protective Factors | 8 | 2021 | 82 | 0.730 |
Why?
|
| Goals | 2 | 2011 | 127 | 0.730 |
Why?
|
| Counseling | 2 | 2019 | 218 | 0.730 |
Why?
|
| Nutrition Policy | 1 | 2021 | 97 | 0.720 |
Why?
|
| Government Regulation | 1 | 2020 | 43 | 0.720 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2021 | 69 | 0.720 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2020 | 3 | 0.720 |
Why?
|
| Budgets | 1 | 2020 | 18 | 0.720 |
Why?
|
| Lipoproteins, LDL | 3 | 2021 | 114 | 0.720 |
Why?
|
| Renal Insufficiency | 4 | 2011 | 232 | 0.710 |
Why?
|
| Rheumatic Fever | 1 | 2020 | 18 | 0.710 |
Why?
|
| Research Design | 2 | 2021 | 646 | 0.710 |
Why?
|
| Denervation | 1 | 2020 | 29 | 0.710 |
Why?
|
| Carotid Arteries | 5 | 2022 | 151 | 0.700 |
Why?
|
| Cardiomyopathies | 4 | 2016 | 479 | 0.700 |
Why?
|
| Biological Specimen Banks | 2 | 2022 | 51 | 0.700 |
Why?
|
| Consensus | 8 | 2024 | 607 | 0.700 |
Why?
|
| Research Report | 9 | 2019 | 69 | 0.690 |
Why?
|
| Interleukins | 1 | 2020 | 116 | 0.690 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 63 | 0.680 |
Why?
|
| Exercise Test | 3 | 2020 | 247 | 0.680 |
Why?
|
| Patient Preference | 1 | 2020 | 100 | 0.670 |
Why?
|
| Health Literacy | 3 | 2019 | 79 | 0.670 |
Why?
|
| Kidney | 6 | 2023 | 1343 | 0.670 |
Why?
|
| Morbidity | 8 | 2020 | 239 | 0.670 |
Why?
|
| Educational Status | 7 | 2023 | 267 | 0.670 |
Why?
|
| Healthy Lifestyle | 5 | 2019 | 29 | 0.660 |
Why?
|
| Echocardiography, Stress | 1 | 2019 | 16 | 0.650 |
Why?
|
| Transients and Migrants | 1 | 2019 | 24 | 0.650 |
Why?
|
| Television | 1 | 2019 | 70 | 0.650 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 140 | 0.650 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2019 | 106 | 0.640 |
Why?
|
| Alcoholism | 1 | 2021 | 229 | 0.640 |
Why?
|
| Biological Products | 1 | 2020 | 112 | 0.630 |
Why?
|
| Emigration and Immigration | 1 | 2019 | 81 | 0.630 |
Why?
|
| Cost-Benefit Analysis | 7 | 2020 | 493 | 0.630 |
Why?
|
| Diuretics | 3 | 2022 | 158 | 0.630 |
Why?
|
| Asia | 7 | 2024 | 105 | 0.630 |
Why?
|
| Metabolic Diseases | 2 | 2019 | 129 | 0.620 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 234 | 0.620 |
Why?
|
| Thinness | 1 | 2019 | 68 | 0.620 |
Why?
|
| Cost of Illness | 5 | 2020 | 240 | 0.620 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 2019 | 234 | 0.620 |
Why?
|
| Health Information Systems | 1 | 2018 | 32 | 0.620 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 408 | 0.610 |
Why?
|
| Aortic Valve | 8 | 2023 | 426 | 0.610 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 168 | 0.610 |
Why?
|
| Texas | 14 | 2024 | 3530 | 0.610 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 357 | 0.600 |
Why?
|
| Patient Care Team | 2 | 2019 | 540 | 0.590 |
Why?
|
| Coronary Stenosis | 3 | 2021 | 70 | 0.580 |
Why?
|
| Survivors | 2 | 2023 | 345 | 0.570 |
Why?
|
| Patient Protection and Affordable Care Act | 4 | 2022 | 63 | 0.570 |
Why?
|
| Asymptomatic Diseases | 6 | 2024 | 77 | 0.570 |
Why?
|
| Pyrimidines | 1 | 2020 | 375 | 0.570 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 139 | 0.560 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 438 | 0.560 |
Why?
|
| Health Services | 2 | 2016 | 71 | 0.550 |
Why?
|
| Propensity Score | 4 | 2012 | 203 | 0.550 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 315 | 0.550 |
Why?
|
| Socioeconomic Factors | 11 | 2023 | 857 | 0.540 |
Why?
|
| Peptide Fragments | 8 | 2023 | 745 | 0.540 |
Why?
|
| Drug Therapy, Combination | 11 | 2021 | 1147 | 0.540 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2013 | 37 | 0.530 |
Why?
|
| Warfarin | 4 | 2021 | 119 | 0.520 |
Why?
|
| Cardiorespiratory Fitness | 3 | 2020 | 10 | 0.520 |
Why?
|
| Drug Utilization | 5 | 2020 | 157 | 0.520 |
Why?
|
| Amino Acids | 2 | 2018 | 660 | 0.520 |
Why?
|
| Colchicine | 4 | 2021 | 42 | 0.510 |
Why?
|
| Inservice Training | 1 | 2016 | 55 | 0.510 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2020 | 501 | 0.500 |
Why?
|
| Angiotensin Receptor Antagonists | 6 | 2024 | 121 | 0.490 |
Why?
|
| Lipoproteins, HDL | 3 | 2024 | 96 | 0.490 |
Why?
|
| Carotid Stenosis | 2 | 2021 | 133 | 0.490 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 4 | 2021 | 44 | 0.490 |
Why?
|
| Niacin | 4 | 2013 | 57 | 0.490 |
Why?
|
| Advisory Committees | 5 | 2019 | 148 | 0.490 |
Why?
|
| Proportional Hazards Models | 15 | 2024 | 1298 | 0.490 |
Why?
|
| Health Status | 8 | 2024 | 370 | 0.490 |
Why?
|
| Angina Pectoris | 1 | 2015 | 57 | 0.480 |
Why?
|
| Heart Injuries | 1 | 2015 | 46 | 0.480 |
Why?
|
| Carotid Artery, Internal | 2 | 2015 | 66 | 0.480 |
Why?
|
| Premature Birth | 1 | 2019 | 380 | 0.480 |
Why?
|
| Heart Ventricles | 2 | 2021 | 767 | 0.480 |
Why?
|
| Carotid Intima-Media Thickness | 8 | 2022 | 72 | 0.480 |
Why?
|
| Attitude to Health | 4 | 2020 | 255 | 0.470 |
Why?
|
| Medical Informatics | 1 | 2016 | 107 | 0.470 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 64 | 0.470 |
Why?
|
| Waist Circumference | 1 | 2014 | 84 | 0.470 |
Why?
|
| Vascular Diseases | 1 | 2016 | 161 | 0.470 |
Why?
|
| Electrocardiography | 7 | 2017 | 963 | 0.460 |
Why?
|
| Bayes Theorem | 3 | 2024 | 265 | 0.460 |
Why?
|
| Wounds, Penetrating | 1 | 2015 | 137 | 0.460 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2021 | 1099 | 0.460 |
Why?
|
| Occupations | 1 | 2014 | 21 | 0.460 |
Why?
|
| Medicare | 5 | 2022 | 418 | 0.460 |
Why?
|
| Athletes | 1 | 2014 | 59 | 0.460 |
Why?
|
| Amyloidosis | 1 | 2015 | 66 | 0.460 |
Why?
|
| Electronic Health Records | 2 | 2018 | 692 | 0.450 |
Why?
|
| Defibrillators, Implantable | 2 | 2024 | 191 | 0.450 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 228 | 0.450 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 115 | 0.450 |
Why?
|
| Echocardiography | 7 | 2023 | 1066 | 0.450 |
Why?
|
| Health Care Surveys | 7 | 2022 | 282 | 0.450 |
Why?
|
| Carotid Artery, Common | 2 | 2011 | 73 | 0.440 |
Why?
|
| Cell Phone | 3 | 2019 | 29 | 0.430 |
Why?
|
| Dementia | 3 | 2023 | 441 | 0.430 |
Why?
|
| Neck | 1 | 2014 | 134 | 0.430 |
Why?
|
| Saphenous Vein | 2 | 2012 | 53 | 0.430 |
Why?
|
| Thrombolytic Therapy | 3 | 2020 | 204 | 0.420 |
Why?
|
| Global Burden of Disease | 2 | 2024 | 25 | 0.420 |
Why?
|
| DNA | 2 | 2020 | 1606 | 0.420 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 220 | 0.420 |
Why?
|
| Kidney Failure, Chronic | 5 | 2023 | 861 | 0.410 |
Why?
|
| Vascular Stiffness | 4 | 2021 | 75 | 0.410 |
Why?
|
| Fenofibrate | 4 | 2014 | 57 | 0.410 |
Why?
|
| Interleukin-6 | 4 | 2023 | 394 | 0.410 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 2 | 2017 | 24 | 0.410 |
Why?
|
| Patient-Centered Care | 3 | 2021 | 222 | 0.400 |
Why?
|
| Hemorrhage | 6 | 2023 | 457 | 0.400 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 507 | 0.400 |
Why?
|
| Heart Valves | 2 | 2010 | 52 | 0.390 |
Why?
|
| Middle East | 2 | 2023 | 33 | 0.390 |
Why?
|
| Oxazolidinones | 1 | 2011 | 36 | 0.390 |
Why?
|
| Cardiologists | 2 | 2023 | 20 | 0.390 |
Why?
|
| Residence Characteristics | 3 | 2022 | 265 | 0.380 |
Why?
|
| Frailty | 2 | 2024 | 98 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2022 | 3448 | 0.380 |
Why?
|
| Heart Valve Diseases | 3 | 2022 | 168 | 0.380 |
Why?
|
| Needs Assessment | 3 | 2023 | 172 | 0.380 |
Why?
|
| Insurance, Health | 3 | 2021 | 134 | 0.370 |
Why?
|
| Awareness | 3 | 2020 | 81 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 58 | 0.370 |
Why?
|
| Pilot Projects | 6 | 2022 | 1363 | 0.370 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2023 | 104 | 0.360 |
Why?
|
| Geography | 2 | 2020 | 112 | 0.360 |
Why?
|
| Medical History Taking | 2 | 2021 | 106 | 0.360 |
Why?
|
| Glomerular Filtration Rate | 5 | 2021 | 480 | 0.360 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 55 | 0.360 |
Why?
|
| Financing, Personal | 2 | 2020 | 10 | 0.350 |
Why?
|
| Data Collection | 3 | 2023 | 383 | 0.350 |
Why?
|
| Drug-Eluting Stents | 5 | 2021 | 53 | 0.350 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2016 | 172 | 0.340 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2020 | 162 | 0.340 |
Why?
|
| Multidetector Computed Tomography | 3 | 2022 | 33 | 0.340 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2023 | 252 | 0.340 |
Why?
|
| Glucosides | 2 | 2020 | 44 | 0.340 |
Why?
|
| Myocardium | 1 | 2015 | 981 | 0.340 |
Why?
|
| Prescriptions | 4 | 2023 | 39 | 0.340 |
Why?
|
| Renin-Angiotensin System | 4 | 2024 | 95 | 0.330 |
Why?
|
| Prasugrel Hydrochloride | 3 | 2021 | 21 | 0.330 |
Why?
|
| Apolipoproteins A | 3 | 2015 | 46 | 0.330 |
Why?
|
| United States Department of Defense | 2 | 2021 | 10 | 0.330 |
Why?
|
| Benzhydryl Compounds | 2 | 2020 | 65 | 0.330 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2023 | 138 | 0.320 |
Why?
|
| Perioperative Care | 5 | 2014 | 195 | 0.320 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2009 | 241 | 0.320 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 2030 | 0.320 |
Why?
|
| Treatment Refusal | 2 | 2019 | 75 | 0.310 |
Why?
|
| RNA Interference | 2 | 2020 | 496 | 0.310 |
Why?
|
| Linear Models | 7 | 2017 | 657 | 0.310 |
Why?
|
| Risk | 6 | 2019 | 744 | 0.310 |
Why?
|
| Medically Uninsured | 5 | 2021 | 73 | 0.310 |
Why?
|
| Creatinine | 3 | 2023 | 379 | 0.300 |
Why?
|
| Developing Countries | 3 | 2020 | 270 | 0.300 |
Why?
|
| Apolipoprotein C-III | 3 | 2020 | 36 | 0.300 |
Why?
|
| Community Health Services | 2 | 2019 | 90 | 0.300 |
Why?
|
| Patient Care Management | 2 | 2021 | 65 | 0.300 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 194 | 0.290 |
Why?
|
| Professional Practice Gaps | 2 | 2018 | 15 | 0.290 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 353 | 0.290 |
Why?
|
| Poverty | 3 | 2022 | 412 | 0.290 |
Why?
|
| Oligonucleotides | 2 | 2020 | 88 | 0.290 |
Why?
|
| Ultrasonography, Doppler | 3 | 2014 | 197 | 0.290 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 279 | 0.290 |
Why?
|
| Phenotype | 11 | 2024 | 4151 | 0.280 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2023 | 457 | 0.280 |
Why?
|
| Patient Compliance | 3 | 2020 | 464 | 0.280 |
Why?
|
| Patient Readmission | 4 | 2023 | 364 | 0.280 |
Why?
|
| Dietary Fats | 2 | 2021 | 288 | 0.280 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2023 | 38 | 0.280 |
Why?
|
| Pericarditis | 2 | 2020 | 41 | 0.270 |
Why?
|
| Apolipoproteins | 2 | 2019 | 68 | 0.270 |
Why?
|
| Influenza, Human | 3 | 2021 | 646 | 0.270 |
Why?
|
| Vaccination | 2 | 2022 | 927 | 0.270 |
Why?
|
| Text Messaging | 2 | 2017 | 30 | 0.270 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2024 | 366 | 0.270 |
Why?
|
| Length of Stay | 8 | 2023 | 1273 | 0.260 |
Why?
|
| United Kingdom | 3 | 2023 | 190 | 0.260 |
Why?
|
| Pneumonia | 3 | 2021 | 325 | 0.260 |
Why?
|
| Computed Tomography Angiography | 2 | 2024 | 195 | 0.260 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2022 | 342 | 0.250 |
Why?
|
| Sex Distribution | 4 | 2024 | 285 | 0.250 |
Why?
|
| Self Report | 3 | 2024 | 498 | 0.250 |
Why?
|
| Health Resources | 2 | 2017 | 115 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2024 | 3050 | 0.250 |
Why?
|
| Subtilisins | 3 | 2021 | 10 | 0.250 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 522 | 0.250 |
Why?
|
| Cost Savings | 4 | 2018 | 69 | 0.250 |
Why?
|
| Heart-Assist Devices | 2 | 2024 | 1022 | 0.240 |
Why?
|
| Clinical Competence | 3 | 2019 | 972 | 0.240 |
Why?
|
| Administration, Oral | 3 | 2021 | 668 | 0.240 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 65 | 0.240 |
Why?
|
| Genetic Variation | 4 | 2015 | 1462 | 0.240 |
Why?
|
| Myocardial Revascularization | 3 | 2021 | 96 | 0.240 |
Why?
|
| Africa | 1 | 2024 | 126 | 0.230 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2024 | 28 | 0.230 |
Why?
|
| Cognition | 2 | 2019 | 732 | 0.230 |
Why?
|
| Vaccination Coverage | 2 | 2021 | 32 | 0.230 |
Why?
|
| Africa, Northern | 1 | 2023 | 9 | 0.230 |
Why?
|
| Internal Medicine | 2 | 2018 | 147 | 0.230 |
Why?
|
| Albuminuria | 3 | 2022 | 91 | 0.220 |
Why?
|
| Persian Gulf Syndrome | 1 | 2023 | 14 | 0.220 |
Why?
|
| Glucose | 3 | 2024 | 875 | 0.220 |
Why?
|
| Metabolic Equivalent | 2 | 2020 | 6 | 0.220 |
Why?
|
| Social Class | 3 | 2022 | 180 | 0.220 |
Why?
|
| Drug Monitoring | 2 | 2021 | 157 | 0.220 |
Why?
|
| Editorial Policies | 1 | 2024 | 50 | 0.220 |
Why?
|
| Leisure Activities | 1 | 2023 | 7 | 0.220 |
Why?
|
| Hearing Aids | 1 | 2023 | 17 | 0.220 |
Why?
|
| Employment | 2 | 2020 | 67 | 0.220 |
Why?
|
| Leg | 2 | 2016 | 153 | 0.210 |
Why?
|
| Live Birth | 1 | 2023 | 54 | 0.210 |
Why?
|
| Writing | 1 | 2024 | 57 | 0.210 |
Why?
|
| Nutrition Assessment | 1 | 2024 | 130 | 0.210 |
Why?
|
| Angioedema | 1 | 2023 | 22 | 0.210 |
Why?
|
| Pessimism | 1 | 2022 | 4 | 0.210 |
Why?
|
| Emigrants and Immigrants | 2 | 2022 | 148 | 0.210 |
Why?
|
| Graves Disease | 1 | 2003 | 16 | 0.210 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 2010 | 0.210 |
Why?
|
| Yoga | 1 | 2023 | 12 | 0.210 |
Why?
|
| Quality of Life | 3 | 2022 | 1913 | 0.210 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 74 | 0.210 |
Why?
|
| Heart Arrest | 3 | 2021 | 341 | 0.210 |
Why?
|
| Multimorbidity | 1 | 2022 | 18 | 0.210 |
Why?
|
| Laboratories | 1 | 2023 | 83 | 0.210 |
Why?
|
| Internship and Residency | 2 | 2018 | 1153 | 0.210 |
Why?
|
| Community Health Workers | 2 | 2023 | 62 | 0.210 |
Why?
|
| Wine | 1 | 2022 | 15 | 0.200 |
Why?
|
| Celiac Disease | 1 | 2023 | 70 | 0.200 |
Why?
|
| Patient Discharge | 3 | 2022 | 487 | 0.200 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 336 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 1679 | 0.200 |
Why?
|
| Myocarditis | 1 | 2023 | 119 | 0.200 |
Why?
|
| Motivation | 3 | 2019 | 312 | 0.200 |
Why?
|
| Resistance Training | 1 | 2022 | 29 | 0.200 |
Why?
|
| Hospitals, Veterans | 4 | 2020 | 353 | 0.200 |
Why?
|
| Mortality, Premature | 1 | 2021 | 10 | 0.200 |
Why?
|
| Overweight | 2 | 2022 | 343 | 0.200 |
Why?
|
| Diet | 2 | 2021 | 1106 | 0.200 |
Why?
|
| Hematoma | 1 | 2022 | 93 | 0.200 |
Why?
|
| Public Health | 1 | 2024 | 253 | 0.200 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 173 | 0.200 |
Why?
|
| Hearing Loss | 1 | 2023 | 132 | 0.200 |
Why?
|
| Models, Economic | 2 | 2019 | 51 | 0.190 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 68 | 0.190 |
Why?
|
| Aging | 4 | 2024 | 1165 | 0.190 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2021 | 5 | 0.190 |
Why?
|
| Animals | 8 | 2021 | 33730 | 0.190 |
Why?
|
| Health Services Misuse | 1 | 2021 | 26 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 1008 | 0.190 |
Why?
|
| Malnutrition | 1 | 2024 | 196 | 0.190 |
Why?
|
| Recurrence | 3 | 2019 | 1413 | 0.190 |
Why?
|
| Dabigatran | 1 | 2021 | 25 | 0.190 |
Why?
|
| Protein Precursors | 3 | 2021 | 150 | 0.190 |
Why?
|
| Galectin 3 | 1 | 2021 | 31 | 0.190 |
Why?
|
| Atrial Appendage | 1 | 2021 | 42 | 0.190 |
Why?
|
| Pancreatitis | 1 | 2022 | 130 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 3 | 2018 | 202 | 0.190 |
Why?
|
| Fish Products | 1 | 2021 | 2 | 0.190 |
Why?
|
| Epidemics | 1 | 2021 | 52 | 0.190 |
Why?
|
| Sleep | 1 | 2024 | 344 | 0.190 |
Why?
|
| Agaricales | 1 | 2020 | 4 | 0.190 |
Why?
|
| Meta-Analysis as Topic | 1 | 2021 | 151 | 0.180 |
Why?
|
| Rural Population | 2 | 2021 | 243 | 0.180 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 17 | 0.180 |
Why?
|
| Fishes | 1 | 2021 | 41 | 0.180 |
Why?
|
| Mental Recall | 1 | 2021 | 138 | 0.180 |
Why?
|
| Reproducibility of Results | 9 | 2023 | 2799 | 0.180 |
Why?
|
| Qualitative Research | 2 | 2021 | 513 | 0.180 |
Why?
|
| Regression Analysis | 2 | 2020 | 755 | 0.180 |
Why?
|
| Risk-Taking | 1 | 2021 | 93 | 0.180 |
Why?
|
| Thiazoles | 1 | 2021 | 96 | 0.180 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2020 | 17 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2023 | 187 | 0.180 |
Why?
|
| Telecommunications | 1 | 2020 | 19 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 227 | 0.180 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2020 | 12 | 0.180 |
Why?
|
| Economic Recession | 1 | 2020 | 2 | 0.180 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 11 | 0.180 |
Why?
|
| Walking | 1 | 2022 | 197 | 0.180 |
Why?
|
| Pyridones | 1 | 2021 | 111 | 0.180 |
Why?
|
| Meditation | 1 | 2020 | 16 | 0.180 |
Why?
|
| Disease Progression | 2 | 2024 | 1992 | 0.180 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 74 | 0.180 |
Why?
|
| Pets | 1 | 2020 | 15 | 0.170 |
Why?
|
| Bioprosthesis | 1 | 2021 | 111 | 0.170 |
Why?
|
| Fever | 1 | 2022 | 295 | 0.170 |
Why?
|
| Prescription Fees | 1 | 2019 | 3 | 0.170 |
Why?
|
| Ownership | 1 | 2020 | 30 | 0.170 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 38 | 0.170 |
Why?
|
| Precision Medicine | 2 | 2022 | 306 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 49 | 0.170 |
Why?
|
| Particulate Matter | 1 | 2020 | 70 | 0.170 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 60 | 0.170 |
Why?
|
| Pyridines | 1 | 2021 | 222 | 0.170 |
Why?
|
| Interleukin-8 | 1 | 2020 | 209 | 0.170 |
Why?
|
| Hospitals | 4 | 2023 | 397 | 0.170 |
Why?
|
| Mental Health | 2 | 2020 | 344 | 0.170 |
Why?
|
| Suburban Population | 1 | 2019 | 5 | 0.170 |
Why?
|
| Observational Studies as Topic | 2 | 2022 | 78 | 0.170 |
Why?
|
| Interleukin-10 | 1 | 2020 | 170 | 0.170 |
Why?
|
| Air Pollution | 1 | 2020 | 66 | 0.170 |
Why?
|
| Ultrasonic Therapy | 1 | 2019 | 31 | 0.170 |
Why?
|
| General Practitioners | 1 | 2019 | 17 | 0.160 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 257 | 0.160 |
Why?
|
| Age Distribution | 4 | 2024 | 401 | 0.160 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 1630 | 0.160 |
Why?
|
| Telomere | 1 | 2020 | 205 | 0.160 |
Why?
|
| Disease Management | 3 | 2020 | 511 | 0.160 |
Why?
|
| Pneumococcal Vaccines | 1 | 2021 | 168 | 0.160 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 1283 | 0.160 |
Why?
|
| Nepal | 1 | 2019 | 9 | 0.160 |
Why?
|
| Down-Regulation | 2 | 2019 | 702 | 0.160 |
Why?
|
| Resuscitation | 1 | 2021 | 240 | 0.160 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 1060 | 0.160 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 59 | 0.160 |
Why?
|
| Chronic Disease | 5 | 2024 | 1167 | 0.160 |
Why?
|
| Heterozygote | 1 | 2021 | 675 | 0.160 |
Why?
|
| Heart | 1 | 2024 | 723 | 0.160 |
Why?
|
| Chest Pain | 2 | 2023 | 125 | 0.160 |
Why?
|
| Health Education | 1 | 2020 | 222 | 0.160 |
Why?
|
| Mass Screening | 2 | 2015 | 781 | 0.160 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 583 | 0.160 |
Why?
|
| Cardiac Catheterization | 3 | 2021 | 631 | 0.160 |
Why?
|
| Air Pollutants | 1 | 2020 | 100 | 0.160 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 187 | 0.160 |
Why?
|
| Sodium | 2 | 2024 | 290 | 0.160 |
Why?
|
| Patients | 1 | 2019 | 120 | 0.160 |
Why?
|
| Pyrazoles | 1 | 2021 | 300 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2021 | 1468 | 0.160 |
Why?
|
| Pulmonary Embolism | 2 | 2019 | 172 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2021 | 274 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 112 | 0.150 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 663 | 0.150 |
Why?
|
| Documentation | 1 | 2019 | 115 | 0.150 |
Why?
|
| Health Facilities | 1 | 2018 | 59 | 0.150 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2017 | 218 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 262 | 0.150 |
Why?
|
| Urban Population | 1 | 2019 | 216 | 0.150 |
Why?
|
| Sick Sinus Syndrome | 1 | 2018 | 12 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2003 | 428 | 0.150 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 293 | 0.150 |
Why?
|
| Blood Pressure Determination | 2 | 2016 | 105 | 0.150 |
Why?
|
| Blood Component Removal | 1 | 2018 | 32 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 671 | 0.150 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2017 | 6 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2022 | 749 | 0.150 |
Why?
|
| Education | 1 | 2018 | 105 | 0.150 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 55 | 0.150 |
Why?
|
| Apolipoprotein A-I | 3 | 2013 | 79 | 0.150 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 188 | 0.150 |
Why?
|
| Cognition Disorders | 2 | 2019 | 551 | 0.150 |
Why?
|
| Thigh | 2 | 2022 | 49 | 0.140 |
Why?
|
| Off-Label Use | 1 | 2017 | 25 | 0.140 |
Why?
|
| Gene Frequency | 3 | 2019 | 703 | 0.140 |
Why?
|
| Confidence Intervals | 2 | 2015 | 277 | 0.140 |
Why?
|
| Arteriosclerosis | 1 | 2017 | 139 | 0.140 |
Why?
|
| Anthropometry | 2 | 2014 | 189 | 0.140 |
Why?
|
| Pharmacists | 1 | 2017 | 83 | 0.140 |
Why?
|
| Lipoprotein Lipase | 2 | 2014 | 54 | 0.140 |
Why?
|
| Rosuvastatin Calcium | 1 | 2016 | 41 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 161 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2020 | 3229 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 215 | 0.130 |
Why?
|
| Stents | 5 | 2016 | 864 | 0.130 |
Why?
|
| Femoral Vein | 1 | 2016 | 50 | 0.130 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 52 | 0.130 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2016 | 31 | 0.130 |
Why?
|
| Religious Personnel | 1 | 2015 | 1 | 0.130 |
Why?
|
| Protestantism | 1 | 2015 | 3 | 0.130 |
Why?
|
| Renal Dialysis | 3 | 2020 | 841 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 2 | 2020 | 87 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 755 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2021 | 676 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 222 | 0.130 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 51 | 0.130 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 170 | 0.130 |
Why?
|
| Occupational Health | 1 | 2015 | 44 | 0.130 |
Why?
|
| Algorithms | 4 | 2016 | 1576 | 0.130 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 22 | 0.120 |
Why?
|
| Research Personnel | 1 | 2016 | 117 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 473 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 352 | 0.120 |
Why?
|
| Intestinal Absorption | 1 | 2016 | 191 | 0.120 |
Why?
|
| Postprandial Period | 1 | 2015 | 75 | 0.120 |
Why?
|
| Prehypertension | 1 | 2015 | 11 | 0.120 |
Why?
|
| Reimbursement, Incentive | 1 | 2015 | 45 | 0.120 |
Why?
|
| Pericardiocentesis | 1 | 2015 | 16 | 0.120 |
Why?
|
| Double-Blind Method | 6 | 2016 | 1570 | 0.120 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2015 | 10 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 187 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 56 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2016 | 237 | 0.120 |
Why?
|
| Mississippi | 2 | 2024 | 30 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2015 | 63 | 0.120 |
Why?
|
| Health Services Research | 2 | 2016 | 185 | 0.120 |
Why?
|
| Angina, Unstable | 1 | 2014 | 51 | 0.120 |
Why?
|
| Decision Making | 1 | 2019 | 650 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 594 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 181 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 231 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2021 | 853 | 0.110 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2015 | 146 | 0.110 |
Why?
|
| Ultrasonography | 2 | 2015 | 941 | 0.110 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 13 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 738 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 585 | 0.110 |
Why?
|
| ROC Curve | 3 | 2012 | 553 | 0.110 |
Why?
|
| Reference Values | 3 | 2011 | 698 | 0.110 |
Why?
|
| Triage | 1 | 2014 | 141 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 872 | 0.110 |
Why?
|
| Brain Infarction | 1 | 2013 | 30 | 0.110 |
Why?
|
| Hyponatremia | 1 | 2014 | 70 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 128 | 0.110 |
Why?
|
| Tangier Disease | 1 | 2012 | 5 | 0.110 |
Why?
|
| Rare Diseases | 1 | 2015 | 179 | 0.110 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 54 | 0.100 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 968 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2010 | 169 | 0.100 |
Why?
|
| Geriatric Assessment | 2 | 2024 | 168 | 0.100 |
Why?
|
| Health Promotion | 1 | 2015 | 385 | 0.100 |
Why?
|
| Problem Solving | 1 | 2012 | 64 | 0.100 |
Why?
|
| General Surgery | 1 | 2014 | 203 | 0.100 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 15 | 0.100 |
Why?
|
| Platelet Aggregation | 2 | 2011 | 120 | 0.100 |
Why?
|
| Mutation | 3 | 2024 | 5735 | 0.100 |
Why?
|
| Vascular Grafting | 1 | 2012 | 44 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2481 | 0.100 |
Why?
|
| Florida | 2 | 2015 | 72 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2012 | 308 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 48 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 190 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 565 | 0.090 |
Why?
|
| Child | 4 | 2020 | 24079 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2012 | 330 | 0.090 |
Why?
|
| Family Practice | 1 | 2011 | 89 | 0.090 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 711 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 126 | 0.090 |
Why?
|
| Platelet Function Tests | 1 | 2011 | 37 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1711 | 0.090 |
Why?
|
| Necrosis | 1 | 2011 | 212 | 0.090 |
Why?
|
| Muscles | 1 | 2011 | 287 | 0.090 |
Why?
|
| Health Policy | 2 | 2023 | 208 | 0.090 |
Why?
|
| Pregnancy | 2 | 2023 | 7093 | 0.090 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 125 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2023 | 555 | 0.090 |
Why?
|
| Forecasting | 2 | 2024 | 355 | 0.090 |
Why?
|
| HIV Infections | 1 | 2022 | 1858 | 0.090 |
Why?
|
| Aftercare | 2 | 2022 | 145 | 0.090 |
Why?
|
| Asia, Western | 2 | 2021 | 3 | 0.090 |
Why?
|
| Particle Size | 2 | 2024 | 115 | 0.090 |
Why?
|
| Nutritional Status | 2 | 2024 | 297 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8097 | 0.080 |
Why?
|
| Machine Learning | 2 | 2022 | 208 | 0.080 |
Why?
|
| Apolipoprotein A-V | 3 | 2015 | 20 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2013 | 514 | 0.080 |
Why?
|
| History, 21st Century | 2 | 2021 | 270 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 1354 | 0.080 |
Why?
|
| Muscle, Skeletal | 3 | 2022 | 923 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2012 | 747 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2011 | 178 | 0.080 |
Why?
|
| Tachycardia, Ventricular | 2 | 2021 | 196 | 0.080 |
Why?
|
| Endocrinology | 1 | 2011 | 139 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 569 | 0.080 |
Why?
|
| Pulse Wave Analysis | 2 | 2021 | 47 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 812 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 234 | 0.080 |
Why?
|
| Syndrome | 2 | 2012 | 1109 | 0.080 |
Why?
|
| Perception | 2 | 2021 | 215 | 0.080 |
Why?
|
| Electric Countershock | 2 | 2020 | 67 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2009 | 63 | 0.080 |
Why?
|
| Sepsis | 1 | 2012 | 472 | 0.080 |
Why?
|
| Peroxidase | 1 | 2008 | 61 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 2 | 2022 | 196 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2009 | 123 | 0.070 |
Why?
|
| Contrast Media | 1 | 2011 | 459 | 0.070 |
Why?
|
| Ankle Brachial Index | 1 | 2007 | 38 | 0.070 |
Why?
|
| Cardiac Tamponade | 1 | 2008 | 37 | 0.070 |
Why?
|
| Phospholipases A2 | 1 | 2007 | 35 | 0.070 |
Why?
|
| Phospholipases A | 1 | 2007 | 39 | 0.070 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2008 | 63 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 2525 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2007 | 117 | 0.070 |
Why?
|
| Cor Triatriatum | 1 | 2007 | 11 | 0.070 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2008 | 78 | 0.070 |
Why?
|
| Acute Disease | 2 | 2022 | 1090 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 522 | 0.070 |
Why?
|
| Long QT Syndrome | 1 | 2007 | 86 | 0.070 |
Why?
|
| Weight Loss | 2 | 2019 | 443 | 0.060 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2005 | 42 | 0.060 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2024 | 13 | 0.060 |
Why?
|
| Massachusetts | 1 | 2024 | 124 | 0.060 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 27 | 0.060 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2024 | 10 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 805 | 0.060 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 517 | 0.060 |
Why?
|
| Oral Health | 1 | 2023 | 17 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 223 | 0.060 |
Why?
|
| Government Programs | 1 | 2023 | 11 | 0.060 |
Why?
|
| Gulf War | 1 | 2023 | 7 | 0.060 |
Why?
|
| Southeastern United States | 1 | 2023 | 38 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2023 | 61 | 0.050 |
Why?
|
| Albumins | 1 | 2023 | 90 | 0.050 |
Why?
|
| Curriculum | 2 | 2019 | 715 | 0.050 |
Why?
|
| World Health Organization | 1 | 2023 | 110 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2025 | 182 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 93 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2018 | 336 | 0.050 |
Why?
|
| Atherectomy | 1 | 2022 | 12 | 0.050 |
Why?
|
| Thiazides | 1 | 2022 | 5 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 160 | 0.050 |
Why?
|
| Tertiary Healthcare | 1 | 2022 | 21 | 0.050 |
Why?
|
| Chlorthalidone | 1 | 2022 | 25 | 0.050 |
Why?
|
| Beer | 1 | 2022 | 4 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2023 | 191 | 0.050 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 34 | 0.050 |
Why?
|
| Microcirculation | 1 | 2022 | 93 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 31 | 0.050 |
Why?
|
| Spain | 1 | 2022 | 53 | 0.050 |
Why?
|
| Alcoholic Beverages | 1 | 2022 | 18 | 0.050 |
Why?
|
| Azetidines | 2 | 2013 | 55 | 0.050 |
Why?
|
| Nigeria | 1 | 2022 | 79 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 80 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 95 | 0.050 |
Why?
|
| Asia, Southeastern | 1 | 2021 | 20 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2017 | 873 | 0.050 |
Why?
|
| New Mexico | 1 | 2021 | 5 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 70 | 0.050 |
Why?
|
| Arizona | 1 | 2021 | 25 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2021 | 28 | 0.050 |
Why?
|
| Smokers | 1 | 2021 | 39 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2021 | 51 | 0.050 |
Why?
|
| Attitude | 1 | 2022 | 119 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 236 | 0.050 |
Why?
|
| California | 1 | 2021 | 127 | 0.050 |
Why?
|
| Data Mining | 1 | 2021 | 52 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 179 | 0.050 |
Why?
|
| Receptors, LDL | 1 | 2021 | 90 | 0.050 |
Why?
|
| Cooking | 1 | 2021 | 36 | 0.050 |
Why?
|
| Ethanol | 1 | 2022 | 162 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2024 | 195 | 0.050 |
Why?
|
| Fertility | 1 | 2023 | 263 | 0.050 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 8 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 24 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 297 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 33 | 0.040 |
Why?
|
| Indians, North American | 1 | 2020 | 58 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 124 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2020 | 32 | 0.040 |
Why?
|
| Marital Status | 1 | 2020 | 34 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 20 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 140 | 0.040 |
Why?
|
| Haplotypes | 2 | 2012 | 510 | 0.040 |
Why?
|
| Cats | 1 | 2020 | 115 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 93 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 103 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 145 | 0.040 |
Why?
|
| Endocarditis | 1 | 2020 | 103 | 0.040 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2025 | 388 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 394 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 156 | 0.040 |
Why?
|
| Food Supply | 1 | 2020 | 97 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 176 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 42 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2019 | 86 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2019 | 68 | 0.040 |
Why?
|
| Cinchona Alkaloids | 1 | 1998 | 1 | 0.040 |
Why?
|
| Certification | 1 | 2019 | 69 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 417 | 0.040 |
Why?
|
| Dogs | 1 | 2020 | 761 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 178 | 0.040 |
Why?
|
| Antimalarials | 1 | 1998 | 37 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 300 | 0.040 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 161 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2020 | 217 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2020 | 303 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 807 | 0.040 |
Why?
|
| Insurance | 1 | 2017 | 6 | 0.040 |
Why?
|
| Acacia | 1 | 1997 | 2 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 384 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 379 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 31 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2019 | 91 | 0.040 |
Why?
|
| Mammography | 1 | 2018 | 113 | 0.040 |
Why?
|
| Fear | 1 | 2019 | 201 | 0.040 |
Why?
|
| Drug Approval | 1 | 2017 | 39 | 0.040 |
Why?
|
| Markov Chains | 1 | 2017 | 79 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2017 | 60 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2018 | 152 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 113 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 156 | 0.040 |
Why?
|
| Drugs, Generic | 1 | 2017 | 13 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2008 | 113 | 0.030 |
Why?
|
| Medicare Part D | 1 | 2016 | 17 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2016 | 33 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2020 | 384 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 23 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 141 | 0.030 |
Why?
|
| Ticlopidine | 1 | 2016 | 28 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2017 | 176 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1997 | 117 | 0.030 |
Why?
|
| Cystatin C | 1 | 2016 | 49 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 161 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2022 | 981 | 0.030 |
Why?
|
| Independent Living | 1 | 2016 | 65 | 0.030 |
Why?
|
| Blood Volume | 1 | 2016 | 79 | 0.030 |
Why?
|
| Adenosine Diphosphate | 2 | 2011 | 58 | 0.030 |
Why?
|
| Sexism | 1 | 2016 | 36 | 0.030 |
Why?
|
| Arachidonic Acid | 2 | 2011 | 70 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1249 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 389 | 0.030 |
Why?
|
| Ultracentrifugation | 1 | 2015 | 20 | 0.030 |
Why?
|
| Cholesterol, VLDL | 1 | 2015 | 14 | 0.030 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2017 | 154 | 0.030 |
Why?
|
| Education, Medical | 1 | 2019 | 285 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 132 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 921 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 736 | 0.030 |
Why?
|
| Utilization Review | 1 | 2015 | 38 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 24 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 268 | 0.030 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 92 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 131 | 0.030 |
Why?
|
| Apolipoprotein B-100 | 1 | 2014 | 33 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2017 | 229 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 175 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 118 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1852 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 42 | 0.030 |
Why?
|
| Exome | 1 | 2018 | 1012 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 83 | 0.030 |
Why?
|
| Patient Admission | 1 | 2014 | 184 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 180 | 0.030 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2013 | 190 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 27 | 0.030 |
Why?
|
| Netherlands | 1 | 2012 | 36 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2012 | 49 | 0.020 |
Why?
|
| Corneal Stroma | 1 | 2012 | 90 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 95 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 17 | 0.020 |
Why?
|
| Metals | 1 | 2012 | 60 | 0.020 |
Why?
|
| Automation | 1 | 2011 | 59 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 511 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 45 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2011 | 24 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 792 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2012 | 239 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2011 | 257 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 393 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 1535 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 447 | 0.020 |
Why?
|
| Retreatment | 1 | 2008 | 88 | 0.020 |
Why?
|
| Pravastatin | 1 | 2008 | 23 | 0.020 |
Why?
|
| Syncope | 1 | 2009 | 52 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1790 | 0.020 |
Why?
|
| Aortography | 1 | 2009 | 200 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2008 | 77 | 0.020 |
Why?
|
| Microspheres | 1 | 2008 | 70 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 631 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 1215 | 0.020 |
Why?
|
| Fluorocarbons | 1 | 2008 | 57 | 0.020 |
Why?
|
| Pyrroles | 1 | 2008 | 177 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1872 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1998 | 4511 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2012 | 13790 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 182 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 1249 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 182 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2938 | 0.010 |
Why?
|
| Calcimycin | 1 | 1998 | 26 | 0.010 |
Why?
|
| Platelet Activating Factor | 1 | 1998 | 29 | 0.010 |
Why?
|
| Epinephrine | 1 | 1998 | 175 | 0.010 |
Why?
|
| Ion Transport | 1 | 1997 | 49 | 0.010 |
Why?
|
| Collagen | 1 | 1998 | 311 | 0.010 |
Why?
|